Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig plus Paclitaxel in second-line SCLC
NCT05879068Phase 2Active, not recruiting
- Sponsor
- Biotheus
- Start
- May 2022
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig in small cell lung cancer (SCLC), sponsored by Biotheus. Started May 2022; status: active, not recruiting.
02
Drugs
pumitamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05879068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879068.